MA48462A - Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation - Google Patents

Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation

Info

Publication number
MA48462A
MA48462A MA048462A MA48462A MA48462A MA 48462 A MA48462 A MA 48462A MA 048462 A MA048462 A MA 048462A MA 48462 A MA48462 A MA 48462A MA 48462 A MA48462 A MA 48462A
Authority
MA
Morocco
Prior art keywords
methods
rankl antibodies
human
human anti
rankl
Prior art date
Application number
MA048462A
Other languages
English (en)
Other versions
MA48462B1 (fr
Inventor
Stephen Robert Brych
Jaymille Fallon
Pavan K Ghattyvenkatakrishna
Monica Michelle Goss
Jian Hua Gu
Lyanne M Wong
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA48462A publication Critical patent/MA48462A/fr
Publication of MA48462B1 publication Critical patent/MA48462B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA48462A 2017-04-28 2018-04-27 Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation MA48462B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492056P 2017-04-28 2017-04-28
PCT/US2018/029728 WO2018200918A1 (fr) 2017-04-28 2018-04-27 Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation

Publications (2)

Publication Number Publication Date
MA48462A true MA48462A (fr) 2020-03-04
MA48462B1 MA48462B1 (fr) 2024-05-31

Family

ID=62165668

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48462A MA48462B1 (fr) 2017-04-28 2018-04-27 Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation

Country Status (34)

Country Link
US (2) US11192952B2 (fr)
EP (2) EP4190355A1 (fr)
JP (3) JP7190822B2 (fr)
KR (2) KR102681171B1 (fr)
AR (1) AR111497A1 (fr)
AU (1) AU2018260750A1 (fr)
BR (1) BR112019022188A2 (fr)
CA (1) CA3054165A1 (fr)
CL (3) CL2019003032A1 (fr)
CO (1) CO2019011463A2 (fr)
CR (1) CR20190538A (fr)
DK (1) DK3615066T3 (fr)
EA (1) EA201992570A1 (fr)
ES (1) ES2973572T3 (fr)
FI (1) FI3615066T3 (fr)
HR (1) HRP20240167T1 (fr)
HU (1) HUE065544T2 (fr)
IL (2) IL293127B2 (fr)
JO (1) JOP20190255A1 (fr)
LT (1) LT3615066T (fr)
MA (1) MA48462B1 (fr)
MX (1) MX2023013460A (fr)
MY (1) MY202479A (fr)
PE (1) PE20200343A1 (fr)
PH (1) PH12019502444A1 (fr)
PL (1) PL3615066T3 (fr)
PT (1) PT3615066T (fr)
RS (1) RS65299B1 (fr)
SG (1) SG11201909998TA (fr)
SI (1) SI3615066T1 (fr)
TN (2) TN2019000297A1 (fr)
TW (1) TWI839331B (fr)
UY (1) UY37707A (fr)
WO (1) WO2018200918A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210079373A (ko) * 2018-11-16 2021-06-29 삼성바이오에피스 주식회사 단백질을 포함하는 안정한 액상 조성물
CN109374779A (zh) * 2018-12-17 2019-02-22 杭州奕安济世生物药业有限公司 一种蔗糖含量的快速检测方法
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
AU2022325870A1 (en) 2021-08-12 2024-02-08 Amgen Inc. Antibody formulations
WO2023092177A1 (fr) * 2021-11-23 2023-06-01 Adalta Limited Molécules de liaison rank -l
CN118139882A (zh) * 2022-03-24 2024-06-04 安济盛生物医药有限公司 骨骼肌肉系统疾病的治疗
WO2024064878A1 (fr) 2022-09-23 2024-03-28 The University Of North Carolina At Chapel Hill Méthodes et compositions pharmaceutiques destinées au traitement du mélanome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2087908B1 (fr) 2001-06-26 2018-05-30 Amgen Inc. Anticorps opgl
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
AU2007338791B2 (en) * 2006-12-21 2014-03-13 Amgen Inc Stable buffered formulations containing polypeptides
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
US20110060290A1 (en) 2008-02-07 2011-03-10 Amgen Inc. Stabilized protein compositions
AR073072A1 (es) 2008-08-19 2010-10-13 Regeneron Pharma Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
US9265834B2 (en) * 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
ES2684921T3 (es) 2010-05-10 2018-10-05 Intas Pharmaceuticals Limited Formulación líquida de polipéptidos que contienen un dominio Fc de una inmunoglobulina
EP2433644A1 (fr) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Traitement du cancer du sein
AU2012243126A1 (en) * 2011-04-07 2013-10-17 Glaxosmithkline Llc Formulations with reduced viscosity
MX352823B (es) 2011-10-28 2017-12-04 Integritybio Inc Formulaciones de proteinas que contienen aminoacidos.
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
US20150274819A1 (en) 2014-03-03 2015-10-01 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
MX2016014411A (es) 2014-05-07 2017-04-06 Takeda Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf.

Also Published As

Publication number Publication date
EP4190355A1 (fr) 2023-06-07
LT3615066T (lt) 2024-02-26
DK3615066T3 (da) 2024-03-11
TN2019000297A1 (en) 2021-05-07
TWI839331B (zh) 2024-04-21
WO2018200918A1 (fr) 2018-11-01
UY37707A (es) 2018-10-31
AU2018260750A1 (en) 2019-08-29
BR112019022188A2 (pt) 2020-05-12
IL268704B (en) 2022-06-01
RS65299B1 (sr) 2024-04-30
EA201992570A1 (ru) 2020-03-20
WO2018200918A8 (fr) 2019-10-17
PL3615066T3 (pl) 2024-04-29
EP3615066A1 (fr) 2020-03-04
HRP20240167T1 (hr) 2024-04-26
CR20190538A (es) 2020-02-26
SI3615066T1 (sl) 2024-04-30
CN110621342A (zh) 2019-12-27
MX2023013460A (es) 2023-12-15
JP2022062059A (ja) 2022-04-19
IL268704A (en) 2019-10-31
KR102681171B1 (ko) 2024-07-05
PT3615066T (pt) 2024-03-08
CA3054165A1 (fr) 2018-11-01
PH12019502444A1 (en) 2020-07-20
JP2023166396A (ja) 2023-11-21
CL2019003032A1 (es) 2020-02-21
JP7190822B2 (ja) 2022-12-16
US20220143181A1 (en) 2022-05-12
HUE065544T2 (hu) 2024-05-28
CL2023002505A1 (es) 2024-03-08
TW201841654A (zh) 2018-12-01
MY202479A (en) 2024-04-30
ES2973572T3 (es) 2024-06-20
CL2020002012A1 (es) 2020-10-16
FI3615066T3 (fi) 2024-02-29
US20200354463A1 (en) 2020-11-12
EP3615066B1 (fr) 2023-12-27
KR20190140464A (ko) 2019-12-19
IL293127B1 (en) 2024-02-01
JP2018188430A (ja) 2018-11-29
US11873343B2 (en) 2024-01-16
PE20200343A1 (es) 2020-02-14
CO2019011463A2 (es) 2019-10-31
JP7356525B2 (ja) 2023-10-04
TN2021000055A1 (en) 2022-10-03
IL293127A (en) 2022-07-01
AR111497A1 (es) 2019-07-17
SG11201909998TA (en) 2019-11-28
IL293127B2 (en) 2024-06-01
KR20240110083A (ko) 2024-07-12
MA48462B1 (fr) 2024-05-31
JOP20190255A1 (ar) 2019-10-27
US11192952B2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA48462A (fr) Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
FR22C1048I2 (fr) Anticorps anti-cd3 et méthodes d'utilisation
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MA43658A (fr) Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA44081A (fr) Anticorps anti-c5 et leurs procédés d'utilisation
MA48852A (fr) Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation
MA56165A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation